241

PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PROOF OF CONCEPT STUDY OF EFFICACY OF RIFAMYCIN SV-MMX® 600 MG ADMINISTERED THREE OR TWO TIMES DAILY TO PATIENTS WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D)

Date
May 18, 2024

Introduction: Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction characterized by abdominal pain associated with bowel movements. Rifaximin -a non-resorbable antibiotic from the rifamycin group- has been shown to be effective in the treatment of non-constipated IBS patients. A novel targeted delivery formulation of rifamycin SV (rifamycin MMX® 600 mg tablets), based on Multimatrix® (MMX®) technology, was developed to provide a more precise delivery of the active substance in the distal small bowel and proximal colon, the region traditionally considered the origin of IBS symptoms.
Aim: To assess the efficacy and safety of rifamycin MMX® for improving symptoms in diarrhea predominant IBS (IBS-D) patients.
Methods: We conducted a randomized, double-blind, placebo-controlled study in 33 European centers. Patients fulfilling Rome IV criteria for IBS-D were randomized to receive either placebo or two different dosing regimens of rifamycin MMX® 600 mg (b.i.d = 1200mg/day or t.i.d =1800mg/day) for 2 weeks. Primary endpoint was the proportion of weekly responders in the first week of treatment assessed on the basis of patients’ daily reported symptoms and stool patterns. Response was defined as a reduction of ≥30% abdominal pain AND ≥50% reduction of weekly days with ≥1 Bristol stool types 6 or 7. Secondary endpoints included adequate relief regarding monthly global symptoms and bloating (adequate relief ≥2 weeks per month) based on weekly questions in the following three months.
Results: 279 patients were randomized to treatment groups that were comparable in terms of demographics and symptoms. A significantly higher percentage in the rifamycin b.i.d. group met the primary endpoint for response based on pain and stool pattern than in the t.i.d. and placebo group (25.0% vs. 12.4% and 9.5% respectively). Adjusted odds ratio for response of b.i.d. vs placebo was 3.26 ([95% CI: 1.39; 7.67], p=0.0066) and t.i.d. vs b.i.d. was 0.40 ([95% CI: 0.17; 0.92]; p=0.0314). There was no significant difference between t.i.d. and placebo (OR 1.30 [95% CI: 0.50; 3.42]; p=0.5892). Monthly global response rate was higher in the b.i.d. group than placebo for the first month and the first two months (66.7% vs 46.5%; OR= 2.36; p=0.0086 and 60.0% vs 42.4%; OR= 2.19; p= 0.0187; respectively). Monthly response for IBS-related bloating was higher in b.i.d. vs placebo (63.3% vs 40.0% 1st month; OR=2.64; p=0.0031 and 59.3% vs 42.4% first 2 months; OR=2.03; p=0.0286 respectively). For the 3 months follow up, monthly global and bloating-related relief were numerically but not statistically higher in the b.i.d. group than in placebo.
Conclusion: In IBS-D, treatment with rifamycin SV-MMX® 600mg b.i.d. was more effective than placebo and t.i.d. dosing in the first week of treatment and provided more adequate relief over the first two months of follow up.
<i>Figure 1</i>: Percentages of patients fulfilling the primary endpoint of composite relief of abdominal pain and stool consistency in the first week of treatment.

Figure 1: Percentages of patients fulfilling the primary endpoint of composite relief of abdominal pain and stool consistency in the first week of treatment.

<i>Figure 2</i>: Percentages of patients reporting adequate relief for ≥2 weeks per month in the first month, the first 2 months and 3 months of follow up. Global = global IBS symptoms, bloating = IBS-related bloating.

Figure 2: Percentages of patients reporting adequate relief for ≥2 weeks per month in the first month, the first 2 months and 3 months of follow up. Global = global IBS symptoms, bloating = IBS-related bloating.


Tracks

Related Products

Thumbnail for WHY DO REFLUX PATIENTS PRESS THE BUTTON? FACTORS CONTRIBUTING TO REAL-TIME ESOPHAGEAL SYMPTOM REPORTING IN REFRACTORY REFLUX PATIENTS
WHY DO REFLUX PATIENTS PRESS THE BUTTON? FACTORS CONTRIBUTING TO REAL-TIME ESOPHAGEAL SYMPTOM REPORTING IN REFRACTORY REFLUX PATIENTS
Introduction: Physiological and psychological factors contribute to gastroesophageal reflux symptoms. However, most research assesses reflux symptom severity via questionnaires…
Thumbnail for PROSPECTIVE EVALUATION OF OPIOID WITHDRAWAL IN PATIENTS WITH SUSPECTED OPIOID-INDUCED ESOPHAGEAL DYSFUNCTION (OIED)
PROSPECTIVE EVALUATION OF OPIOID WITHDRAWAL IN PATIENTS WITH SUSPECTED OPIOID-INDUCED ESOPHAGEAL DYSFUNCTION (OIED)
Opioid-induced esophageal dysfunction (OIED) is a recognized consequence of chronic opioid use, manifesting mainly as non-obstructive dysphagia and esophageal motility abnormalities documented in manometry studies including type III achalasia, hypercontractile esophagus, distal esophageal spasm, an…
Thumbnail for COMBINED BODY SURFACE GASTRIC MAPPING AND GASTRIC EMPTYING TESTING REVEALS DISTINCT PATIENT SUBGROUPS IN GASTROPARESIS
COMBINED BODY SURFACE GASTRIC MAPPING AND GASTRIC EMPTYING TESTING REVEALS DISTINCT PATIENT SUBGROUPS IN GASTROPARESIS
BACKGROUND: Gastric emptying testing is used to diagnose gastroparesis. However, gastroparesis is a heterogeneous disorder that may involve several distinct underlying pathophysiologies related to impaired gastric function…
Thumbnail for DUODENAL T CELL PROFILE PREDICTS RESPONSE TO HIGH-DOSE PROTON PUMP INHIBITORS IN FUNCTIONAL DYSPEPSIA
DUODENAL T CELL PROFILE PREDICTS RESPONSE TO HIGH-DOSE PROTON PUMP INHIBITORS IN FUNCTIONAL DYSPEPSIA
I: Functional dyspepsia (FD) is a chronic gastrointestinal (GI) disorder with incompletely understood pathophysiology…